H.C. Wainwright assumed coverage of 89bio (ETNB) with a Buy rating and $32 price target The company is advancing a FGF21 analog pegozafermin into pivotal trials with broad fibrosis potential, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
- 89bio price target lowered to $29 from $30 at BofA
- 89bio Reports Q2 2025 Financial Results and Updates
- 89Bio Inc. Faces Financial Uncertainty Amid Potential U.S. Tax Law Changes
- 89bio reports Q2 EPS (71c), consensus (48c)
- 89Bio Inc.’s ENTRUST Study: A Potential Game-Changer in Hypertriglyceridemia Treatment